| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Creativity Management - The Value of Being Prolific |
|
Main Subject - Creativity Management - The Value of Being Prolific
When asked his secret to success, the author Graham Green said that it was down to his always writing According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product 500 words a day. There are real reasons why this philosophy rings true: a) The single best creative ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in product tends to appear at that point in the career when the creator is being most prolific – qualit lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. y of output is closely related to quantity. b) In the early stages, relative lack of experience, kno here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ledge and refined methodology limits performance to sub-optimal levels. With time these factors impro d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ve and productivity increases exponentially. The experience curve implies that creativity should get ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc easier and faster the more it is engaged in. c) The major part of learning takes place subliminally easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi and unconsciously. When we are strongly motivated by an endeavour, we will become good at it by worki nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically g on it at various cognitive levels. d) Many skilled actions are initially learnt with much consciou and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s effort then, with practice, they come easily and smoothly (subliminal perception and learning). Aft ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi er complete automisation, paying complete attention can actually be detrimental. e) Incremental targ ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ets produce more output than a “do your best” approach. If a leader asks participants in an idea gene dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ating session to address a problem and think of at least 5 ideas every half an hour, then 80 ideas ar cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin e produced by one individual and 1600 are produced by 20 individuals at the end of an average working tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen day. This level of output is conscious and would not be produced normally. This topic is covered in t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel depth in the MBA dissertation on Managing Creativity & Innovation, which can be purchased (along wit ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust a Creativity and Innovation DIY Audit, Good Idea Generator Software and Power Point Presentation) fr y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products om http://www.managing-creativity.com. You can also receive a regular, free newsletter by entering yo . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ur email address at this site. Kal Bishop, MBA ********************************** You are free to elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Secrets to Getting that Dream Job in IT
|